Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.

EBioMedicine · 2017 · PMC5360580 · PMID 28259590

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

nearly significantP = 0.067so close (0.05 < p ≤ 0.1)

In mild AD patients, WMS-R improved significantly in the treatment group, and the between group difference was nearly significant (P = 0.067).

also in 3,279 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.